Gold Nanoparticles Treatment Reverses Brain Damage in Alzheimer’s Disease Model

Tramontin, Natalia dos Santos; Silva, Sabrina da; Arruda, Rychard; Ugioni, Kellen Simon; Canteiro, Paula Bortuluzzi; Silveira, Gustavo de Bem; Mendes, Carolini; Silveira, Paulo César Lock; Müller, Alexandre Pastoris

doi:10.1007/s12035-019-01780-w

Cited by 105 publications

(63 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once it was previously demonstrated gold nanoparticles can modify some cellular processes, such as signaling pathways, intracellular ROS concentration and proteins expression [26,27,28], we verified whether AuNPs were uptaken or not by the GL261 tumor cells in an attempt to explain why no change in tumor volume was observed after chronically treating mice with cit-AuNP. To measure the traffic of gold nanoparticles through the GL261 cell membrane, we used fluorescent gold nanoparticles (DY654-AuNPs).…”

Section: Gold Nanoparticles Were Not Uptaken By the Gl261 Cellsmentioning

confidence: 72%

“…Besides, a reactive oxygen species (ROS)-rich microenvironment favors a series of epigenetic alterations that further support the GBM progression, for example, changes in the deoxyribonucleic acid (DNA) methylation and acetylation of histones, with consequent DNA repair enzymes malfunctioning [24,25]. Once some studies have demonstrated an antioxidative effect of 20 nm citrate-covered gold nanoparticles, they could potentially reduce the GBM growing [26,27]. Furthermore, it was reported that gold nanoparticles reduce tumor cells proliferation, enhances caspase 3 and 8 expressions, and reduces Bcl-2 and the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) expressions [28,29].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gold nanoparticles carrying or not anti-VEGF antibody do not change glioblastoma multiforme tumor progression in mice

Silva

Colli

et al. 2020

Heliyon

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most devastating malignant primary brain tumor known. Life expectance is around 15 months after diagnosis. Several events contribute to the GBM progression such as uncontrolled genetic cancer cells proliferation, angiogenesis (mostly vascular endothelial growth factor (VEGF)mediated), tissue invasion, glioma stem cell activity, immune system failure, and a hypoxic and inflammatory tumor microenvironment. Tumor cells antiproliferative effect of 20 nm citrate-covered gold nanoparticles (cit-AuNP) has been reported, along with anti-inflammatory and anti-oxidative effects. We aimed to test whether either chronic treatment with 20 nm cit-AuNP or anti-VEGF antibody (Ig)-covered AuNP could reduce GBM progression in mice. Main methods: Effect of the gold nanoparticles on the GL261 glioblastoma cells proliferation in vitro, and on the GL261-induced glioblastoma cell growth in C57BL/6 mice in vivo were tested. Besides, fluorophore-conjugated gold nanoparticles penetration through the GL261 plasma cell membrane, gold labelling in brain parenchyma of glioblastoma-carrying mice, and VEGF expression into the tumor were evaluated. Key findings: We observed cit-AuNP did no change the GL261 cells proliferation. Similarly, we demonstrated chronic treatment with either cit-AuNP or anti-VEGF Ig-covered AuNP did not modify the GL261 cells-induced GBM progression in mice. By the end, we showed AuNPs did not trespass in appreciable amount both the GL261 plasma cell membrane and the tumoral blood brain barrier (BBB), and did not change the VEGF expression into the tumor. Significance: 20 nm cit-AuNP or anti-VEGF Ig covered-AuNP are not good tools to reduce GBM in mice, probably because they do not penetrate both tumor cells and BBB in enough amount to reduce tumor growing.

show abstract

Section: Gold Nanoparticles Were Not Uptaken By the Gl261 Cellsmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 99%

Gold nanoparticles carrying or not anti-VEGF antibody do not change glioblastoma multiforme tumor progression in mice

Silva

Colli

et al. 2020

Heliyon

View full text Add to dashboard Cite

show abstract

“…A recent study indicates that administration of maize tetrapeptideanchored gold NPs can improve central cholinergic system function and reduce the level of acetylcholinesterase, suggesting that novel tetrapeptide can be used as a neuroprotective agent to prevent AD (Zhang et al, 2021). Another study has reported that treatment with AuNPs in AD animals has significantly reversed the symptoms of AD by reducing neuroinflammation and modulating mitochondrial functions (Dos Santos Tramontin et al, 2020).…”

Section: Gold Npsmentioning

confidence: 99%

Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

Khan

Mir

Ngowi

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a devastating disease of the aging population characterized by the progressive and slow brain decay due to the formation of extracellular plaques in the hippocampus. AD cells encompass tangles of twisted strands of aggregated microtubule binding proteins surrounded by plaques. Delivering corresponding drugs in the brain to deal with these clinical pathologies, we face a naturally built strong, protective barrier between circulating blood and brain cells called the blood–brain barrier (BBB). Nanomedicines provide state-of-the-art alternative approaches to overcome the challenges in drug transport across the BBB. The current review presents the advances in the roles of nanomedicines in both the diagnosis and treatment of AD. We intend to provide an overview of how nanotechnology has revolutionized the approaches used to manage AD and highlight the current key bottlenecks and future perspective in this field. Furthermore, the emerging nanomedicines for managing brain diseases like AD could promote the booming growth of research and their clinical availability.

show abstract

“…Alternatively, the treatment of 5XFAD mice with vitamin D-binding protein-loaded PLGA NPs attenuates cognitive defects by inhibiting Aβ binding and accumulation (Jeon et al, 2019). Au NPs have also been reported to induce cytoprotective effects in AD rat model by promoting anti-inflammatory responses and improving antioxidant status (Dos Santos Tramontin et al, 2020). Furthermore, surface-coated Au NPs have also been shown to reduce Aβ aggregation, with the effect varying with the diameter and surface chemistry of the NPs (Moore et al, 2017).…”

Section: Admentioning

confidence: 99%

The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders

Ngowi

Wang

Qian

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Brain is by far the most complex organ in the body. It is involved in the regulation of cognitive, behavioral, and emotional activities. The organ is also a target for many diseases and disorders ranging from injuries to cancers and neurodegenerative diseases. Brain diseases are the main causes of disability and one of the leading causes of deaths. Several drugs that have shown potential in improving brain structure and functioning in animal models face many challenges including the delivery, specificity, and toxicity. For many years, researchers have been facing challenge of developing drugs that can cross the physical (blood–brain barrier), electrical, and chemical barriers of the brain and target the desired region with few adverse events. In recent years, nanotechnology emerged as an important technique for modifying and manipulating different objects at the molecular level to obtain desired features. The technique has proven to be useful in diagnosis as well as treatments of brain diseases and disorders by facilitating the delivery of drugs and improving their efficacy. As the subject is still hot, and new research findings are emerging, it is clear that nanotechnology could upgrade health care systems by providing easy and highly efficient diagnostic and treatment methods. In this review, we will focus on the application of nanotechnology in the diagnosis and treatment of brain diseases and disorders by illuminating the potential of nanoparticles.

show abstract

Gold Nanoparticles Treatment Reverses Brain Damage in Alzheimer’s Disease Model

Cited by 105 publications

References 70 publications

Gold nanoparticles carrying or not anti-VEGF antibody do not change glioblastoma multiforme tumor progression in mice

Gold nanoparticles carrying or not anti-VEGF antibody do not change glioblastoma multiforme tumor progression in mice

Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders

Contact Info

Product

Resources

About